Literature DB >> 8650611

Hypothesis: compartmentalization of cytokines in intraabdominal infection.

M Schein1, D H Wittmann, R Holzheimer, R E Condon.   

Abstract

BACKGROUND: Although the proximal role of systemic cytokines in the infectious-inflammatory cascades is well recognized, the magnitude and meaning of its intraperitoneal levels in peritonitis have received little attention. We hypothesized that in peritonitis a significant and clinically relevant cytokine-mediated inflammatory response is compartmentalized in the peritoneal cavity.
METHODS: MEDLINE was used to search the literature for all articles dealing with experimental, primary, and secondary bacterial peritonitis and cytokines.
RESULTS: Bacterial peritonitis is associated with an immense intraperitoneally compartmentalized cytokine response, with plasma levels of cytokines representing only the tip of the iceberg. Although certain amount of cytokines may be beneficial to the peritoneal defense mechanisms, higher levels correlate with adverse outcome. Thus it is plausible to look at acute peritonitis as initially a combined infective (microorganism) and inflammatory (cytokines) process. The clinical significance of the distinction between peritoneal inflammation and infection and the relevance of our findings to the stratification and treatment of peritonitis are discussed.
CONCLUSIONS: Current surgical and antibiotic therapy for peritonitis is able to clear the peritoneal cavity of infective concentration of bacteria, but many patients continue to die of an uncontrolled activation of the inflammatory cascade. We suggest that one potential venue for therapeutic progress is the modulation of the compartmentalized peritoneal inflammatory response.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8650611     DOI: 10.1016/s0039-6060(96)80195-4

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  20 in total

Review 1.  Management of peritonitis in the critically ill patient.

Authors:  Carlos A Ordoñez; Juan Carlos Puyana
Journal:  Surg Clin North Am       Date:  2006-12       Impact factor: 2.741

Review 2.  [Relaparotomy in secondary peritonitis Planned relaparotomy or relaparotomy on demand?].

Authors:  B Lamme; C W Mahler; J W O van Till; O van Ruler; D J Gouma; M A Boermeester
Journal:  Chirurg       Date:  2005-09       Impact factor: 0.955

3.  Does loss of body protein determine outcome in patients who are critically ill?

Authors:  D W Wilmore
Journal:  Ann Surg       Date:  1998-08       Impact factor: 12.969

Review 4.  Secondary peritonitis: principles of diagnosis and intervention.

Authors:  James T Ross; Michael A Matthay; Hobart W Harris
Journal:  BMJ       Date:  2018-06-18

Review 5.  The significance of endotoxin release in experimental and clinical sepsis in surgical patients--evidence for antibiotic-induced endotoxin release?

Authors:  R G Holzheimer
Journal:  Infection       Date:  1998 Mar-Apr       Impact factor: 3.553

6.  Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa peritonitis in a murine model.

Authors:  N A Barekzi; K A Poelstra; A G Felts; I A Rojas; J B Slunt; D W Grainger
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

7.  Gender-specific differences in sex hormones and cytokines in patients undergoing major abdominal surgery.

Authors:  Stefan Scheingraber; Daniel Dobbert; Peter Schmiedel; Ewald Seliger; Henning Dralle
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

Review 8.  Multiple organ failure. How valid is the "two hit" model?

Authors:  R Saadia; M Schein
Journal:  J Accid Emerg Med       Date:  1999-05

9.  Protein C as an early marker of severe septic complications in diffuse secondary peritonitis.

Authors:  Aleksandar Karamarkovic; Dejan Radenkovic; Natasa Milic; Vesna Bumbasirevic; Branislav Stefanovic
Journal:  World J Surg       Date:  2005-06       Impact factor: 3.352

Review 10.  Primary and secondary peritonitis: an update.

Authors:  M Laroche; G Harding
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-08       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.